<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Revandkar, Ajinkya</dc:creator>
  <dc:creator>Perciato, Maria Luna</dc:creator>
  <dc:creator>Toso, Alberto</dc:creator>
  <dc:creator>Alajati, Abdullah</dc:creator>
  <dc:creator>Chen, Jingjing</dc:creator>
  <dc:creator>Gerber, Hermeto</dc:creator>
  <dc:creator>Dimitrov, Mitko</dc:creator>
  <dc:creator>Rinaldi, Andrea</dc:creator>
  <dc:creator>Delaleu, Nicolas</dc:creator>
  <dc:creator>Pasquini, Emiliano</dc:creator>
  <dc:creator>D’Antuono, Rocco</dc:creator>
  <dc:creator>Pinton, Sandra</dc:creator>
  <dc:creator>Losa, Marco</dc:creator>
  <dc:creator>Gnetti, Letizia</dc:creator>
  <dc:creator>Arribas, Alberto</dc:creator>
  <dc:creator>Fraering, Patrick</dc:creator>
  <dc:creator>Bertoni, Francesco</dc:creator>
  <dc:creator>Nepveu, Alain</dc:creator>
  <dc:creator>Andrea Alimonti</dc:creator>
  <dc:date>2016-12-12</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Activation of NOTCH signalling is associated with advanced prostate cancer and treatment resistance  in prostate cancer patients. However, the mechanism that drives NOTCH activation in prostate  cancer remains still elusive. Moreover, preclinical evidence of the therapeutic efficacy of NOTCH  inhibitors in prostate cancer is lacking. Here, we provide evidence that PTEN loss in prostate tumours  upregulates the expression of ADAM17, thereby activating NOTCH signalling. Using prostate  conditional inactivation of both Pten and Notch1 along with preclinical trials carried out in Pten-null  prostate conditional mouse models, we demonstrate that Pten-deficient prostate tumours are  addicted to the NOTCH signalling. Importantly, we find that pharmacological inhibition of γ-secretase  promotes growth arrest in both Pten-null and Pten/Trp53-null prostate tumours by triggering cellular  senescence. Altogether, our findings describe a novel pro-tumorigenic network that links PTEN loss  to ADAM17 and NOTCH signalling, thus providing the rational for the use of γ-secretase inhibitors in  advanced prostate cancer patients.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319005</dc:identifier>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1319005</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319005/files/Revandkar_NC_2016.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/ncomms13719</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319005</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Nature communications. - 2016, vol. 7, p. 13719</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cancer genetics</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Prostate cancer</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
